Austrian biotech (Graz) developing antibody-drug conjugates using its GoldenSite site-specific conjugation platform.
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Funding round Austria's VALANX Biotech raised EUR 3M, including new backers Foundation Fournier-Majoie and Fujifilm, to advance its ADC for metastatic triple-negative breast cancer. | $3.5M |
| Nov 2023 | Growth Austrian synthetic-biology firm VALANX Biotech raised EUR2.3M in a growth round led by SkyGene to develop its protein conjugation platform. | $2.5M |